• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌肺段切除术预后的相关因素:日本某单一机构的长期随访研究

Factors associated with outcome of segmentectomy for non-small cell lung cancer: long-term follow-up study at a single institution in Japan.

作者信息

Okumura Meinoshin, Goto Masashi, Ideguchi Kan, Tamura Mitsunobu, Sasaki Hidefumi, Tanaka Hisaichi, Matsumura Akihide, Iuchi Keiji

机构信息

Department of Surgery, National Hospital Organization, Kinki Medical Center for Chest Diseases, 1181 Nagasone-Cho, Sakai-City, Osaka 591-8555, Japan.

出版信息

Lung Cancer. 2007 Nov;58(2):231-7. doi: 10.1016/j.lungcan.2007.06.014. Epub 2007 Jul 30.

DOI:10.1016/j.lungcan.2007.06.014
PMID:17673328
Abstract

A lobectomy is the standard surgical procedure for non-small cell lung cancer (NSCLC), though recently a limited resection is more likely chosen for small-sized early stage disease. To elucidate the effectiveness of an intentional segmentectomy as a curative procedure, factors associated with survival after the procedure were examined in a long-term retrospective study carried out at a single institute. Patients with stage I, II, or III disease NSCLC who underwent a segmentectomy between 1980 and 2002 (n = 144) were retrospectively studied and the results compared with those who underwent a lobectomy during the same period (n = 1241). Tumor size, nodal involvement, pleural involvement, and histological type were independent significant prognostic factors in patients who received a segmentectomy. Six patients had a large cell carcinoma and each died from the disease within 5 years after the segmentectomy. In patients with p-T1N0M0 (stage IA) disease and a tumor smaller than 2 cm, except for large cell carcinomas, the 5- and 10-year survival rates were 83% and 83%, respectively, after a segmentectomy, and 81% and 64%, respectively, after a lobectomy (p = 0.66). In patients with p-T1N0M0 disease and a tumor diameter exceeding 2 cm, the 5- and 10-year survival rates were 58% and 58%, respectively, after a segmentectomy, and 78% and 60%, respectively, after a lobectomy (p = 0.057). We concluded that histological type and tumor size were relevant for determining the indication of an intentional segmentectomy for NSCLC with stage IA disease.

摘要

肺叶切除术是治疗非小细胞肺癌(NSCLC)的标准外科手术,不过最近对于早期小尺寸疾病更倾向于选择局限性切除术。为了阐明意向性肺段切除术作为一种根治性手术的有效性,在一家机构进行的一项长期回顾性研究中,对该手术后与生存相关的因素进行了检查。对1980年至2002年间接受肺段切除术的Ⅰ、Ⅱ或Ⅲ期NSCLC患者(n = 144)进行回顾性研究,并将结果与同期接受肺叶切除术的患者(n = 1241)进行比较。肿瘤大小、淋巴结受累情况、胸膜受累情况和组织学类型是接受肺段切除术患者的独立显著预后因素。6例患者为大细胞癌,每例均在肺段切除术后5年内死于该疾病。对于p-T1N0M0(ⅠA期)疾病且肿瘤小于2 cm的患者,除大细胞癌外,肺段切除术后5年和10年生存率分别为83%和83%,肺叶切除术后分别为81%和64%(p = 0.66)。对于p-T1N0M0疾病且肿瘤直径超过2 cm的患者,肺段切除术后5年和10年生存率分别为58%和58%,肺叶切除术后分别为78%和60%(p = 0.057)。我们得出结论,组织学类型和肿瘤大小与确定ⅠA期NSCLC意向性肺段切除术的适应证相关。

相似文献

1
Factors associated with outcome of segmentectomy for non-small cell lung cancer: long-term follow-up study at a single institution in Japan.非小细胞肺癌肺段切除术预后的相关因素:日本某单一机构的长期随访研究
Lung Cancer. 2007 Nov;58(2):231-7. doi: 10.1016/j.lungcan.2007.06.014. Epub 2007 Jul 30.
2
Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection.肿瘤大小对非小细胞肺癌患者预后的影响:肺段切除术作为一种较小切除方式的作用
J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93. doi: 10.1016/j.jtcvs.2004.04.030.
3
Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins--implications for patient selection for segmentectomy.IA期非小细胞肺癌肺段切除术后局部复发频率受肺段定位和手术切缘宽度的影响——对肺段切除术患者选择的启示
Eur J Cardiothorac Surg. 2007 Mar;31(3):522-7; discussion 527-8. doi: 10.1016/j.ejcts.2006.12.018. Epub 2007 Jan 16.
4
Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer.非小细胞肺癌袖状肺叶切除术后的发病率、死亡率和长期生存率
Eur J Cardiothorac Surg. 2007 Jan;31(1):95-102. doi: 10.1016/j.ejcts.2006.10.031. Epub 2006 Nov 28.
5
Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis.肺叶切除术与节段切除术治疗 I 期非小细胞肺癌的生存比较:一项基于人群的分析。
Ann Thorac Surg. 2011 Dec;92(6):1943-50. doi: 10.1016/j.athoracsur.2011.05.091. Epub 2011 Oct 1.
6
Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer.解剖性肺段切除术治疗Ⅰ期非小细胞肺癌。
Ann Thorac Surg. 2007 Sep;84(3):926-32; discussion 932-3. doi: 10.1016/j.athoracsur.2007.05.007.
7
Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly.老年I期非小细胞肺癌的解剖性肺段切除术
Ann Thorac Surg. 2009 Jun;87(6):1662-6; discussion 1667-8. doi: 10.1016/j.athoracsur.2009.02.097.
8
["Intentionally" limited pulmonary resection versus lobectomy for the treatment of peripheral stage IA non-small cell lung cancers].["意向性"肺叶切除术与肺叶切除术治疗周围型ⅠA期非小细胞肺癌的对比]
G Chir. 2007 Jan-Feb;28(1-2):7-12.
9
Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections.IA期非小细胞肺癌的肺叶下切除:肺段切除术相比楔形切除术,癌症相关生存率显著更高。
Eur J Cardiothorac Surg. 2008 Apr;33(4):728-34. doi: 10.1016/j.ejcts.2007.12.048. Epub 2008 Feb 7.
10
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.基于现行分期系统,肿瘤大小对 1A 期非小细胞肺癌解剖性肺切除术后结局的影响。
J Thorac Cardiovasc Surg. 2012 Feb;143(2):390-7. doi: 10.1016/j.jtcvs.2011.10.023. Epub 2011 Dec 9.

引用本文的文献

1
Analysis of clinical and oncological outcomes after simple and intentional lung segmentectomies: the deceptive simplicity of the S6 segment.单纯性与意向性肺段切除术后的临床及肿瘤学结局分析:S6段的表面简单性
J Thorac Dis. 2025 Jun 30;17(6):3809-3819. doi: 10.21037/jtd-24-1348. Epub 2025 Jun 26.
2
Endobronchial indocyanine green instillation to identify the intersegmental plane for successful segmentectomy.支气管内注入吲哚菁绿以识别节段间平面,从而成功进行节段切除术。
Respirol Case Rep. 2023 Jun 19;11(7):e01174. doi: 10.1002/rcr2.1174. eCollection 2023 Jul.
3
Usefulness of pyruvate dehydrogenase-E1α expression to determine SUVmax cut-off value of [F]FDG-PET for predicting lymph node metastasis in lung cancer.
丙酮酸脱氢酶-E1α 表达在确定 [F]FDG-PET SUVmax 截断值预测肺癌淋巴结转移中的作用。
Sci Rep. 2023 Jan 28;13(1):1565. doi: 10.1038/s41598-023-28805-8.
4
[Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection 
after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer].[新辅助化疗免疫治疗后局部晚期中央型肺癌开胸手术及机器人辅助支气管袖状切除术的经验]
Zhongguo Fei Ai Za Zhi. 2022 Feb 20;25(2):71-77. doi: 10.3779/j.issn.1009-3419.2021.101.46.
5
Lobectomy is superior to segmentectomy for peripheral high grade non-small cell lung cancer ≤2 cm.对于直径≤2cm的周围型高分级非小细胞肺癌,肺叶切除术优于肺段切除术。
J Thorac Dis. 2020 Oct;12(10):5925-5933. doi: 10.21037/jtd-20-1530.
6
Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment.临床 T1N0 期非小细胞肺癌的选择性节段切除术:不同节段的生存结果存在差异。
Ann Thorac Surg. 2021 Mar;111(3):1028-1035. doi: 10.1016/j.athoracsur.2020.05.166. Epub 2020 Jul 31.
7
Analysis of Segmental Lymph Node Metastasis and Clinical Features in cT1N0M0 Lung Adenocarcinoma.cT1N0M0 期肺腺癌的节段性淋巴结转移分析及临床特征。
Biomed Res Int. 2020 Feb 18;2020:2842604. doi: 10.1155/2020/2842604. eCollection 2020.
8
A Meta-Analysis Comparing Lobectomy versus Segmentectomy in Stage I Non-Small Cell Lung Cancer.一项比较Ⅰ期非小细胞肺癌肺叶切除术与肺段切除术的Meta分析。
Korean J Thorac Cardiovasc Surg. 2019 Aug;52(4):195-204. doi: 10.5090/kjtcs.2019.52.4.195. Epub 2019 Aug 5.
9
Postoperative recurrence of clinical early-stage non-small cell lung cancers: a comparison between solid and subsolid nodules.临床早期非小细胞肺癌术后复发:实性和亚实性结节的比较。
Cancer Imaging. 2019 Jun 7;19(1):33. doi: 10.1186/s40644-019-0219-3.
10
Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging.I期肺腺癌的复发风险:一项关于手术类型与淋巴结分期类型之间协同作用的多机构研究。
J Thorac Dis. 2019 Feb;11(2):564-572. doi: 10.21037/jtd.2019.01.31.